Pre-made Bifikafusp benchmark antibody ( Whole mAb Fusion, anti-FN extra domain B therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bifikafusp biosimilar, Whole mAb Fusion: Anti-FN extra domain B therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Bifikafusp biosimilar, Whole mAb Fusion: Anti-FN extra domain B therapeutic antibody |
|---|---|
| INN Name | Bifikafusp |
| Target | FN extra domain B |
| Format | Whole mAb Fusion |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgE |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Philogen |
| Conditions Approved | NA |
| Conditions Active | Non-small cell lung cancer,Diffuse large B-cell lymphoma,[With onfekafusp] Malignant melanoma,[With onfekafusp] Basal cell cancer,[With onfekafusp] Squamous cell cancer,[With onfekafusp] Solid tumour |
| Conditions Discontinued | Malignant melanoma,Renal cell carcinoma,Solid tumours,Atherosclerosis,Head and neck cancer,Pancreatic cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FN extra domain B |
| Package |
